FDA Grants Breakthrough Therapy Designation to Glycomine's GLM101 for PMM2-CDG
核心洞察
The FDA has granted Breakthrough Therapy Designation to Glycomine's GLM101, a liposomal mannose-1-phosphate substrate replacement therapy for PMM2-CDG (搜索), a multisystem disorder with no approved treatments.
The designation rests on open-label Phase 2a data in which nine adult and adolescent patients showed a mean 11.9-point improvement on the ICARS ataxia scale over 24 weeks.
GLM101 is now being tested in the global, randomized, double-blind, placebo-controlled Phase 2b POLAR study, which enrolled 43 pediatric and adult patients across 15 sites.
Glycomine, Inc. has received US FDA Breakthrough Therapy Designation (BTD) for GLM101, an investigational liposomal mannose-1-phosphate (M1P) substrate replacement therapy for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG (搜索)). The San Carlos, California-based company announced the designation on September 23, 2026. PMM2-CDG is a serious, multisystem disorder for which no approved treatments currently exist.
The designation follows Fast Track Designation granted to GLM101 for the same indication on September 18, 2024. Under FDA policy, Breakthrough Therapy Designation is available for investigational drugs intended to treat serious conditions when preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint. The designation is intended to support more efficient development and review through closer engagement with the agency.
Mechanism and Phase 2a Evidence
GLM101 bypasses loss-of-function mutations in the PMM2 (搜索) enzyme by delivering mannose-1-phosphate directly into cells via a liposomal nanoparticle, restoring the N-glycosylation pathway without requiring functional PMM2 activity. The therapy is designed to address the underlying deficiency in mannose-1-phosphate and the resulting disruption of glycosylation in PMM2-CDG (搜索).
The BTD is grounded in data from an open-label Phase 2a study in which nine adult and adolescent patients treated with GLM101 showed a mean 11.9-point improvement on the International Cooperative Ataxia Rating Scale (ICARS) over 24 weeks. ICARS is scored from 0 to 100, with higher scores indicating greater impairment. No serious adverse events were reported in the Phase 2a study, and all adverse events were characterized as mild to moderate in severity. The FDA's decision also cites improvements in ataxia and other clinical measures after 24 weeks of treatment.
"This designation reflects the compelling clinical evidence generated to date and the urgent need for a treatment for people living with PMM2-CDG (搜索)," said Steven Axon, Chief Executive Officer of Glycomine. "It also gives us the opportunity for more frequent discussions with FDA as we analyze the POLAR data and determine the next steps for GLM101."
POLAR Phase 2b Design and Timeline
GLM101 is currently being evaluated in POLAR (NCT06892288), a global, randomized, double-blind, placebo-controlled Phase 2b study that enrolled 43 pediatric and adult patients with PMM2-CDG (搜索) across 15 sites in the United States, United Kingdom, and Europe. Ataxia improvement as measured by ICARS serves as the primary endpoint. Topline data from the randomized portion of POLAR are expected in the fourth quarter of 2026.
Following the randomized portion, all patients may receive GLM101 through Week 48, which the company states will provide additional information on longer-term safety, durability of response, and the experience of patients who cross from placebo to GLM101.
Competitive Landscape in PMM2-CDG
A separate PMM2-CDG (搜索) program has evaluated oral epalrestat, an aldose reductase (搜索) inhibitor approved in Japan for diabetic neuropathy, in a randomized Phase 3 pediatric study. That trial was terminated for futility in 2025, leaving GLM101 as one of the more advanced active development programs specifically targeting PMM2-CDG.